Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
- 804 Downloads
Schizophrenia is a chronic medical condition with periods of remission and relapses over a patient’s lifetime. Antipsychotic medications represent the mainstay of treatment for this disease. Long-acting injectable (LAI) formulations of antipsychotics are an attractive alternative to their oral counterparts, as they enhance patient adherence. A number of second-generation antipsychotics (SGAs) are available in LAI formulations. These include paliperidone, aripiprazole, olanzapine, and risperidone. This article reviews the most recently developed and approved of these formulations—aripiprazole monohydrate, aripiprazole lauroxil, and paliperidone palmitate. While all were initially available as once-monthly formulations, a paliperidone palmitate 3-monthly injection formulation has been approved and is the first LAI agent to extend the dosing administration beyond the typical monthly time period. In addition, aripiprazole lauroxil every 6-week and 8-week administration preparations have been developed. LAI preparations of the SGAs have all demonstrated superiority over placebo and are comparable to their oral counterparts in terms of safety and tolerability, if injection site reactions are not taken into account. First-generation antipsychotic LAI preparations (e.g., haloperidol decanoate) have recently been compared with SGA LAI agents, and both formulations demonstrated comparable efficacy with the expected adverse events seen with each drug. Despite their availability, barriers to the use of LAIs remain. Education of both patients and clinicians on the use of LAI formulations and the continued development of these agents are important steps in ensuring these medications are available to the patients they would be most likely to benefit.
Compliance with Ethical Standards
No funds from any sources were used to assist with the preparation of this review article.
Conflict of interest
Michael W. Jann is on Janssen’s Speaker Bureau. Scott R. Penzak has no conflicts of interest.
- 5.Hunter J. Intramuscular injection techniques. Nurs Stand. 2008;22:35–40.Google Scholar
- 8.Risperdal® Consta® (risperidone) package insert, Ortho-McNeil Janssen Pharmaceuticals, Inc. revised 2010.Google Scholar
- 9.Zyprexa® Relprevv® (olanzapine pamoate) package insert, Eli Lilly and Company, 2009.Google Scholar
- 10.Invega® Sustenna® (paliperidone palmitate) package insert, Janssen Pharmaceuticals, Inc. 2009.Google Scholar
- 11.Invega® Trinza™ (paliperidone palmitate) package insert, Janssen Pharmaceuticals, Inc. 2015.Google Scholar
- 14.Abilify® Maintena® (aripiprazole monohydrate) package insert, Otsuka Pharmaceuticals, 2017.Google Scholar
- 15.Aristada™ (aripiprazole lauroxil) package insert, Alkermes, Inc. 2015.Google Scholar
- 16.Kennedy WK. Where and how to use long-acting injections. Curr Psychiatry. 2012;11:1–8.Google Scholar
- 17.Hill CL, Phadke D, Boyce KM. Four-week iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder. In: Poster presented at: 161st annual meeting of the American Psychiatric Association; May 3–8, 2008; Washington DC.Google Scholar
- 28.Turncliff R, Hard M, Du Y, Risinger R, Ehrich EW. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159:404–10.CrossRefPubMedGoogle Scholar
- 31.Cleton A, Rossenu S, Crauwels H, et al. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol. 2014;54:1048–57.CrossRefPubMedGoogle Scholar
- 38.Lopez LV, Kane JM. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. J Clin. 2015;76:1249–50.Google Scholar
- 70.Anand E, Berggren L, Deix C, Toth A, McDonnell DP. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. Neuropsychiatry Dis Treat. 2015;11:1349–57.CrossRefGoogle Scholar
- 74.Schreiner A, Bergmans P, Cherubin P, Hargarter L. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Ther Adv Psychopharmacol. 2017;7:59–65.CrossRefPubMedGoogle Scholar
- 76.Anderson JP, Icten Z, Alas V, Benson C, Joshi K. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17:346. https://doi.org/10.1186/212888-071-1507-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 78.Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr. 2017;22:17–27.Google Scholar